Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded to Strong-Buy at Cantor Fitzgerald

Zealand Pharma A/S (OTCMKTS:ZLDPF) was upgraded by equities research analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Separately, JPMorgan Chase & Co. started coverage on Zealand Pharma A/S in a research note on Friday, November 8th. They issued an “overweight” rating on the stock.

Zealand Pharma A/S Stock Performance

Shares of Zealand Pharma A/S stock opened at $102.98 on Tuesday. The business has a fifty day simple moving average of $102.26 and a two-hundred day simple moving average of $117.80. The firm has a market capitalization of $7.31 billion, a P/E ratio of -42.38 and a beta of 0.89. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03. Zealand Pharma A/S has a 12 month low of $65.26 and a 12 month high of $141.74.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.